Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel

PURPOSE: Patients with neuroblastoma in molecular remission remain at considerable risk for disease recurrence. Studies have found that neuroblastoma tissue contains adrenergic (ADRN) and mesenchymal (MES) cells; the latter express low levels of commonly used markers for minimal residual disease (MR...

Descripción completa

Detalles Bibliográficos
Autores principales: van Wezel, Esther M., van Zogchel, Lieke M.J., van Wijk, Jalenka, Timmerman, Ilse, Vo, Ngoc-Kim, Zappeij-Kannegieter, Lily, deCarolis, Boris, Simon, Thorsten, van Noesel, Max M., Molenaar, Jan J., van Groningen, Tim, Versteeg, Rogier, Caron, Huib N., van der Schoot, C. Ellen, Koster, Jan, van Nes, Johan, Tytgat, Godelieve A.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133311/
https://www.ncbi.nlm.nih.gov/pubmed/34036221
http://dx.doi.org/10.1200/PO.18.00413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133311/
https://www.ncbi.nlm.nih.gov/pubmed/34036221
http://dx.doi.org/10.1200/PO.18.00413

Ejemplares similares